UK – NICE publishes draft guidance not recommending CSL’s haemophilia B gene therapy
The National Institute for Health and Care Excellence (NICE) has issued a draft Appraisal Consultation Document that does not recommend CSL Behring’s Hemgenix (etranacogene dezaparvovec) gene therapy for haemophilia B.
The Draft guidance document can be found on the NICE website.
More information on RIS.World and PMLive.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (12 mars 2024). UK – NICE publishes draft guidance not recommending CSL’s haemophilia B gene therapy. ELSIBI. Consulté le 19 janvier 2025 à l’adresse https://doi.org/10.58079/w08b
